Healthcare provider profile · identity verified

Timothy Jon Leaman, M.D.

Family Practice · PHILADELPHIA, PA · NPI 1346291481

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	212	50
Metformin Hcl	Metformin Hcl	170	37
Amlodipine Besylate	Amlodipine Besylate	168	36
Omeprazole	Omeprazole	153	33
Albuterol Sulfate Hfa	Albuterol Sulfate	144	23
Trulicity	Dulaglutide	133	16
Lisinopril	Lisinopril	130	33
Gabapentin	Gabapentin	109	24
Pantoprazole Sodium	Pantoprazole Sodium	99	16
Famotidine	Famotidine	97	23
Fluticasone Propionate	Fluticasone Propionate	95	20
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	90	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	88	16
Hydrochlorothiazide	Hydrochlorothiazide	86	17
Levothyroxine Sodium	Levothyroxine Sodium	77	13
Metoprolol Succinate	Metoprolol Succinate	75	16
Losartan Potassium	Losartan Potassium	70	13
Citalopram Hbr	Citalopram Hydrobromide	63	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	61	16
Tizanidine Hcl	Tizanidine Hcl	57	12
Chlorthalidone	Chlorthalidone	53	13
Tivicay	Dolutegravir Sodium	53	suppressed
Ibuprofen	Ibuprofen	48	suppressed
Meloxicam	Meloxicam	48	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	46	suppressed
Jardiance	Empagliflozin	43	suppressed
Naproxen	Naproxen	43	12
Finasteride	Finasteride	42	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	41	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	40	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	40	suppressed
Montelukast Sodium	Montelukast Sodium	38	suppressed
Ozempic	Semaglutide	37	suppressed
Furosemide	Furosemide	36	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	35	suppressed
Glipizide Er	Glipizide	34	suppressed
Clopidogrel	Clopidogrel Bisulfate	33	suppressed
Lidocaine Hcl Viscous	Lidocaine Hcl	33	suppressed
Alprazolam	Alprazolam	32	suppressed
Single Use Swab	Alcohol Antiseptic Pads	32	suppressed
Breo Ellipta	Fluticasone/Vilanterol	31	suppressed
Potassium Chloride	Potassium Chloride	31	suppressed
Hydralazine Hcl	Hydralazine Hcl	29	suppressed
Pravastatin Sodium	Pravastatin Sodium	28	suppressed
Ammonium Lactate	Ammonium Lactate	27	suppressed
Diazepam	Diazepam	27	suppressed
Mirtazapine	Mirtazapine	27	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	26	suppressed
Allopurinol	Allopurinol	26	suppressed
Descovy	Emtricitabine/Tenofov Alafenam	26	suppressed
Nifedipine Er	Nifedipine	26	suppressed
Nitroglycerin	Nitroglycerin	26	suppressed
Ketoconazole	Ketoconazole	25	suppressed
Alendronate Sodium	Alendronate Sodium	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Loperamide	Loperamide Hcl	24	suppressed
Sertraline Hcl	Sertraline Hcl	24	suppressed
Juluca	Dolutegravir/Rilpivirine	23	suppressed
Mupirocin	Mupirocin	23	suppressed
Arnuity Ellipta	Fluticasone Furoate	22	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	21	suppressed
Varenicline Tartrate	Varenicline Tartrate	21	suppressed
Ventolin Hfa	Albuterol Sulfate	21	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Triumeq	Abacavir/Dolutegravir/Lamivudi	20	suppressed
Warfarin Sodium	Warfarin Sodium	20	suppressed
Buspirone Hcl	Buspirone Hcl	19	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Lidocaine	Lidocaine	19	suppressed
Linzess	Linaclotide	19	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	18	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	18	suppressed
Eliquis	Apixaban	18	suppressed
Doxepin Hcl	Doxepin Hcl	17	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	17	suppressed
Carvedilol	Carvedilol	16	suppressed
Clobetasol Propionate	Clobetasol Propionate	16	suppressed
Irbesartan	Irbesartan	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	15	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	14	suppressed
Genvoya	Elviteg/Cob/Emtri/Tenof Alafen	14	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	14	suppressed
Spiriva Respimat	Tiotropium Bromide	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	13	suppressed
Bydureon Bcise	Exenatide Microspheres	13	suppressed
Calcipotriene	Calcipotriene	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Endocet	Oxycodone Hcl/Acetaminophen	13	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Lactulose	Lactulose	13	suppressed
Lamivudine Hbv	Lamivudine	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Odefsey	Emtricitab/Rilpiviri/Tenof Ala	13	suppressed
Vemlidy	Tenofovir Alafenamide	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Spiriva Handihaler	Tiotropium Bromide	12	suppressed
Alcohol Swab	Alcohol Antiseptic Pads	11	suppressed
Baclofen	Baclofen	11	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Haloperidol	Haloperidol	11	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Tramadol Hcl	Tramadol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error